Authors: Pierpaolo Pellicori MD, John G.F. Cleland MD, PhD, Maria Borentain MD, Jorg Taubel MD, Fraser Graham MB ChB, Javed Khan MB ChB, Dario Bruzzese PhD, Paul Kessler MD, John J.V. McMurray MD, Adriaan A. Voors MD, PhD, Christopher M. O'Connor MD, John R. Teerlink MD, G. Michael Felker MD, MHSIn a recent publication in the European Journal of Heart Failure (November 2023), the impact of cimlanod, a vasodilator, on diuretic response in congestive heart failure patients is explored. Download

Richmond Pharmacology has a team of experts with extensive knowledge of clinical research trials.

Careers at Richmond

We are on the lookout for people who love what they do, strive for excellence and who want to make a difference.

Our Videos

Learn more about Richmond Pharmacology by viewing some of our videos.

Latest news

Regulatory Pathways to Success

January 9, 2026

Structured pathways to accelerate development and approval.

Clinical Trials Innovation Programme

10 - 11 February 2026

Richmond Pharmacology is pleased to attend the Clinical Trials Innovation Programme Conference in Nice, France, 10–11 February 2026.

View event

Impact of vasodilators on diuretic response in patients with congestive heart failure: a mechanistic trial of cimlanod (BMS-986231)

For patients with heart failure and congestion, vasodilation with agents such as cimlanod reduces the response to diuretic agents, which may offset any benefit from acute reductions in cardiac preload and afterload.

Meet the experts

Careers at Richmond

Our Videos

Latest news

Regulatory Pathways to Success

Events

Clinical Trials Innovation Programme

About us

Knowledge Base

Connect with us